Current Beat
Mar | 31 | 2025
Press Release
Remix Therapeutics™ to Present at Stifel 2025 Virtual Targeted Oncology Forum
Watertown, Mass. (March 31, 2025) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Stifel 2025 Virtual Targeted Oncology Forum on […]
Nov | 26 | 2024
Press Release
Remix Therapeutics™ to Present at 7th Annual Evercore HealthCONx Conference
Cambridge, Mass. (November 26, 2024) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the 7th Annual Evercore HealthCONx Conference in Miami […]
Nov | 20 | 2024
Press Release
Remix Therapeutics™ to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)
REM-422, a First-in-Class Small Molecule MYB mRNA Degrader, Demonstrates Anti-Leukemic Activity as Monotherapy and in Combination in Preclinical Models of AML WATERTOWN, Mass., November 20, 2024 – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced an upcoming oral presentation […]
It's Sound Science



